A Phase 1/2 interventional study of Tadalafil- Tablet or Oral suspension in Pulmonary Arterial Hypertension, sponsored by Eli Lilly and Company. Completed at 16 sites in 6 countries. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2019-10-09.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 312 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.
Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 169th largest by enrollment of the 253 interventional ones that give a count, is one of 14 that started in 2012, is one of 7 in phase 1/2, and was the 111th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →38 of the 312 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
35Pharma Inc., a GSK company · Sites in United States, Spain, United Kingdom
Ages 18+
Insmed Incorporated · Sites in United States, Argentina, Australia and 5 more countries
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 6 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
312 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 94 · Phase 3 73 · Phase 4 33
First in 2002; this study’s year is marked. 14 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 40 across the 253 interventional studies, 67 across the 59 observational. Of the 235 that completed or were terminated, 133 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
186 of 312 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 2 studies filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
18 of the studies in Pulmonary Arterial Hypertension with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06274801Phase 3Gossamer Bio USA, Inc.Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | 2026-12 |
| NCT05649748Phase 3Insmed IncorporatedAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | 2026-12-31 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT07312227Massachusetts General HospitalA Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see how much study drug is in the blood of children with pulmonary arterial hypertension (PAH) after dosing to establish the correct dose for further clinical research.
During Period I, tadalafil will be administered orally, once daily, at a low dose for approximately 5 weeks followed by a high dose for approximately 5 weeks. Dose levels are calculated based on body weight cohorts. Heavy weight cohort >=40 kg, middle weight cohort >=25 kg to \<40 kg. Light weight cohort\<25 kg. Participants who complete Period 1 may continue taking tadalafil in Period 2 for at least 2 years. Starting dose will not exceed the maximum weight range dose established in Period 1 and after the first 3 months of Period 2, the dose may be adjusted based on available safety and efficacy information.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Currently have a diagnosis of PAH that is either:
Exclusion Criteria:
History of left-sided heart disease, including any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Light Weight \<25 kg Period 1: 2 milligram (mg) or 4 mg tadalafil administered once daily (QD) in oral suspension formulation for 5 weeks then 8 mg,10 mg,15 mg or 20 mg tadalafil was administered QD in oral suspension formulation for 5 weeks. Middle Weight: 25 kg to \<40 kg Period 1: 5 mg tadalafil tablet administered QD for 5 weeks then 10 mg, 15 mg or 20 mg tablet tadalafil administered QD for 5 weeks. Heavy: ≥40 kg Period 1: 10 mg tadalafil tablet administered QD for 5 weeks then 20 mg or 40 mg tablet tadalafil administered QD for 5 weeks.
Drug: Tadalafil- Tablet or Oral suspension
Tadalafil Tablets administered orally. Tadalafil Oral suspension: An aqueous, ready-to-use suspension for oral administration.
Also known as: LY450190
Population Pharmacokinetics: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau) for Tadalafil
Population Pharmacokinetics: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau) for Tadalafil. The measure of dispersion reported is 90% Prediction Intervals and not Confidence Intervals.
Time frame: Period 1: Pre Dose and 2, 4, 8, 12, and 24 Hours Post Dose on Days 1, 14 and 49; with single dose measures on Day 1 and steady-state measurements on Days 14 and 49
Population Pharmacokinetics: Average Concentration (Cmean,ss) of for Tadalafil at Steady-State.
Population Pharmacokinetics: Average Concentration (Cmean,ss) of for tadalafil at steady-state. The measure of dispersion reported is 90% Prediction Intervals and not Confidence Intervals.
Time frame: Period 1: Pre Dose and 2, 4, 8, 12, and 24 Hours Post Dose on Days 1, 14 and 49; with single dose measures on Day 1 and steady-state measurements on Days 14 and 49
Percentage of Participants With Clinical Worsening
Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).
Time frame: Baseline Up to 27 Months
Number of Participants With Palatability of the Tadalafil Suspension
The Taste Assessment Questionnaire (TAQ) questions were: TAQRES1: Please rate the bitterness level. TAQRES2: Please rate the sweetness level. TAQRES3: Please rate the aftertaste. TAQRES4: Please rate the overall acceptability of the taste for daily use.
Time frame: Day 35 (high dose)
Per protocol, the summary was based on weight cohorts.
| Milestone | Light Weight <25 kg | Middle Weight: 25 kg to <40 kg | Heavy Weight: ≥40 kg |
|---|---|---|---|
| Started | 6 | 7 | 6 |
| Received 2 mg | 1 | 0 | 0 |
| Received 4 mg | 5 | 0 | 0 |
| Received 5 mg | 0 | 7 | 0 |
| Received 10 mg | 0 | 0 | 6 |
| Completed | 6 | 7 | 6 |
| Not completed | 0 | 0 | 0 |
| Milestone | Light Weight <25 kg | Middle Weight: 25 kg to <40 kg | Heavy Weight: ≥40 kg |
|---|---|---|---|
| Started | 6 | 7 | 6 |
| Received 8 mg | 1 | 0 | 0 |
| Received 10 mg | 1 | 1 | 0 |
| Received 15 mg | 1 | 1 | 0 |
| Received 20 mg | 3 | 5 | 1 |
| Received 40 mg | 0 | 0 | 5 |
| Completed | 6 | 6 | 6 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Milestone | Light Weight <25 kg | Middle Weight: 25 kg to <40 kg | Heavy Weight: ≥40 kg |
|---|---|---|---|
| Started | 6 | 6 | 6 |
| Received 7 mg | 1 | 0 | 0 |
| Received 7.5 mg | 0 | 2 | 0 |
| Received 8 mg | 1 | 0 | 0 |
| Received 10 mg | 0 | 1 | 0 |
| Received 15 mg | 1 | 2 | 1 |
| Received 20 mg | 3 | 1 | 4 |
| Received 40 mg | 0 | 0 | 1 |
| Completed | 5 | 5 | 4 |
| Not completed | 1 | 1 | 2 |
| Withdrew: Death | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 |
Population Pharmacokinetics: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau) for Tadalafil. The measure of dispersion reported is 90% Prediction Intervals and not Confidence Intervals.
| nanograms* hour per milliliter(ng*hr/mL) | 20 mg Light Weight: <25 kg | 20 mg Middle Weight: 25 kg to <40 kg | 40 mg Heavy Weight: ≥40 kg |
|---|---|---|---|
| Not Taking Bosentan | 8170 (3850 to 16700) | 8390 (4130 to 18400) | 15200 (6980 to 31100) |
| Taking Concomitant Bosentan | 4550 (2170 to 9450) | 5000 (2440 to 10600) | 8990 (4270 to 19500) |
Population Pharmacokinetics: Average Concentration (Cmean,ss) of for tadalafil at steady-state. The measure of dispersion reported is 90% Prediction Intervals and not Confidence Intervals.
| nanograms per milliliter (ng/mL) | 20 mg Light Weight <25 kg | 20 mg Middle Weight: 25 kg to <40 kg | 40 mg Heavy Weight: ≥40 kg |
|---|---|---|---|
| Not Taking Bosentan | 340 (161 to 694) | 350 (172 to 767) | 633 (291 to 1300) |
| Taking Concomitant Bosentan | 190 (90.4 to 394) | 209 (102 to 440) | 375 (178 to 815) |
Clinical worsening was defined as any of the following: death, lung or heart transplantation, atrial septostomy or Potts' shunt, hospitalization for Pulmonary Arterial Hypertension (PAH) progression, new onset syncope, initiation of new PAH therapy (including increase in the dose of existing PAH specific concomitant therapy, such as endothelin receptor agonist or beraprost medication), or increase of 1 or more in World Health Organization(WHO) Functional Class (except for participants already in Class IV; only for participants unable to perform the 6 minute walk (6MW) test; worsening of WHO functional class by 1 or more for participants who can perform a 6 minute walk (6MW) test and who have a decrease of ≥ 20% in the 6 minute walk distance (for those participants who are ≥6 years of age).
| percentage of participants | Light Weight <25 kg | Middle Weight: 25 kg to <40 kg | Heavy Weight: ≥40 kg |
|---|---|---|---|
| Percentage of Participants With Clinical Worsening | 50.00 | 28.57 | 33.33 |
The Taste Assessment Questionnaire (TAQ) questions were: TAQRES1: Please rate the bitterness level. TAQRES2: Please rate the sweetness level. TAQRES3: Please rate the aftertaste. TAQRES4: Please rate the overall acceptability of the taste for daily use.
| Participants | Light Weight: <25 kg |
|---|---|
| TAQRES1: Extremely bitter | 0 |
| TAQRES1: Very bitter | 0 |
| TAQRES1: Moderately bitter | 0 |
| TAQRES1: Slightly bitter | 0 |
| TAQRES1: Not bitter | 3 |
| TAQRES2: Extremely sweet | 1 |
| TAQRES2: Very sweet | 0 |
| TAQRES2: Moderately sweet | 1 |
| TAQRES2: Slightly sweet | 1 |
| TAQRES2: Not sweet | 0 |
| TAQRES3: Extreme aftertaste | 0 |
| TAQRES3: Strong aftertaste | 1 |
| TAQRES3: Moderate aftertaste | 0 |
| TAQRES3:Slight aftertaste | 0 |
| TAQRES3:No aftertaste | 2 |
| TAQRES4: Not acceptable | 0 |
| TAQRES4: Slightly acceptable | 0 |
| TAQRES4: Acceptable | 2 |
| TAQRES4: Very acceptable | 1 |
Collected over Up To 27 Months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Light Weight: <25 kg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Middle Weight: 25 kg to <40 kg | 1/7 (14.3%) | 4/7 (57.1%) | 7/7 (100%) |
| Heavy Weight: ≥40 kg | 1/6 (16.7%) | 3/6 (50%) | 6/6 (100%) |
| Event | Light Weight: <25 kg | Middle Weight: 25 kg to <40 kg | Heavy Weight: ≥40 kg |
|---|---|---|---|
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 1/6 | 1/7 | 2/6 |
| Ovarian cystReproductive system and breast disorders | 0/4 | 0/5 | 1/4 |
| Pneumonia viralInfections and infestations | 1/6 | 0/7 | 0/6 |
| Viral infectionInfections and infestations | 0/6 | 1/7 | 1/6 |
| PresyncopeNervous system disorders | 1/6 | 0/7 | 0/6 |
| SyncopeNervous system disorders | 1/6 | 0/7 | 0/6 |
| Cardiac failureCardiac disorders | 0/6 | 1/7 | 0/6 |
| GastritisGastrointestinal disorders | 0/6 | 1/7 | 0/6 |
| PyrexiaGeneral disorders | 0/6 | 1/7 | 0/6 |
| Type 1 diabetes mellitusMetabolism and nutrition disorders | 0/6 | 1/7 | 0/6 |
| Event | Light Weight: <25 kg | Middle Weight: 25 kg to <40 kg | Heavy Weight: ≥40 kg |
|---|---|---|---|
| GastroenteritisInfections and infestations | 3/6 | 0/7 | 1/6 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/6 | 3/7 | 0/6 |
| Angina pectorisCardiac disorders | 1/6 | 0/7 | 2/6 |
| Ear painEar and labyrinth disorders | 0/6 | 0/7 | 2/6 |
| VomitingGastrointestinal disorders | 2/6 | 2/7 | 1/6 |
| PyrexiaGeneral disorders | 2/6 | 1/7 | 1/6 |
| BronchitisInfections and infestations | 2/6 | 1/7 | 0/6 |
| NasopharyngitisInfections and infestations | 2/6 | 1/7 | 2/6 |
| Respiratory tract infectionInfections and infestations | 0/6 | 0/7 | 2/6 |
| HeadacheNervous system disorders | 2/6 | 2/7 | 2/6 |
Participants who received at least one dose of study drug. Participants were first administered a low dose to explore PK of tadalafil and determine a high dose within the weight cohort. Per protocol, the summary was based on weight cohorts.
| Age, Continuous(years) | Light Weight: <25 kg | Middle Weight: 25 kg to <40 kg | Heavy Weight: ≥40 kg | Total |
|---|---|---|---|---|
| Mean | 5.00 (2.5 to 8.0) | 10.91 (7.3 to 17.9) | 14.45 (11.3 to 17.6) | 10.16 (2.5 to 17.9) |
| Sex: Female, Male(Participants) | Light Weight: <25 kg | Middle Weight: 25 kg to <40 kg | Heavy Weight: ≥40 kg | Total |
|---|---|---|---|---|
| Female | 4 | 5 | 4 | 13 |
| Male | 2 | 2 | 2 | 6 |
| Race (NIH/OMB)(Participants) | Light Weight: <25 kg | Middle Weight: 25 kg to <40 kg | Heavy Weight: ≥40 kg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 4 | 5 | 5 | 14 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Light Weight: <25 kg | Middle Weight: 25 kg to <40 kg | Heavy Weight: ≥40 kg | Total |
|---|---|---|---|---|
| Canada | 3 | 1 | 1 | 5 |
| United States | 1 | 0 | 1 | 2 |
| Poland | 1 | 2 | 2 | 5 |
| United Kingdom | 0 | 3 | 0 | 3 |
| France | 0 | 1 | 1 | 2 |
| Spain | 1 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2012 to primary completion in Apr 2017, 57 months.
Results were first posted in Feb 2019, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil
Pulmonary Arterial Hypertension →